Drug target profile analysis revealed increased safety concerns due to genomic features (i.e., constraint, molecular interactions, and tissue specificity) for polyQ disorder genes, particularly ATN1, ATXN1, ATXN7, and HTT. PolyQ disorder genes also showed significantly more safety-related risks than HD genetic modifier genes (p = 7.03 × 10−3). Here, ATN1 is linked to Huntington disease.